Ricevi le ultime notizie sulle azioni Minerva Neurosciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di NERV

Ultime notizie per

MINERVA NEUROSCIENCES INC

Minerva Neurosciences

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences Inc

NERVGEN PHARMA CORP by NervGen Pharma Corp.

NervGen Pharma Corp

NerveNetwork

Nervos Network

Earnings

Press Releases

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

News

Health Care

Financing

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved

NERV

AlphaTON Capital

BioAtla

Boundless Bio

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Dyadic International, Inc. - Common Stock

Dyadic International

Elutia

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Lantern Pharma

LAVA Therapeutics

Mural Oncology

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Pluri

Q32 Bio

Rein Therapeutics

RenovoRx

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tenax Therapeutics

Exicure

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

XOMA Royalty

8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th

Comments

Minerva Neurosciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO